[Atrial fibrillation--etiology, pathophysiological mechanisms, and therapy].
Kageyama
Toshimi
T
Cardiopulmonary Division, Department of Internal Medicine, Keio University School of Medicine.
Ogawa
Satoshi
S
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D017115:Catheter Ablation; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D020257:Ventricular Remodeling
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants